Cell
Volume 51, Issue 6, 24 December 1987, Pages 1063-1070
Journal home page for Cell

Article
Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

https://doi.org/10.1016/0092-8674(87)90592-7Get rights and content

Abstract

The epidermal growth factor receptor (EGFR) gene is frequently amplified and/or overexpressed in human malignancies. To investigate the biological effects of its overexpression, we constructed a eukaryotic vector containing human EGFR cDNA. Introduction of this construct led to reconstitution of functional EGF receptors in NR6 mutant cells, which are normally devoid of this receptor. Transfection of NIH 3T3 resulted in no significant alterations in growth properties. However, EGF addition led to the formation of densely growing transformed foci in liquid culture and colonies in semisolid medium. NIH 3T3-EGFR clonal lines, which expressed the EGF at 500- to 1000-fold levels over control NIH 3T3 cells, demonstrated a marked increase in DNA synthesis in response to EGF. Thus EGF receptor overexpression appears to amplify normal EGF signal transduction. Finally, high levels of EGFR expression, which conferred a transformed phenotype to NIH 3T3 cells in the presence of ligand, were demonstrated in representative human tumor cell lines that contained amplified copies of the EGFR gene.

References (51)

  • C.J. Sherr et al.

    The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1

    Cell

    (1985)
  • M. Wigler et al.

    Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells

    Cell

    (1977)
  • M.M. Wrann et al.

    Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line

    J. Biol. Chem.

    (1979)
  • T. Yamamoto et al.

    The erbB gene of avian erythroblastosis virus is a member of the src gene family

    Cell

    (1983)
  • J. Yokota et al.

    Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo

    Lancet

    (1986)
  • R. Cailleau et al.

    Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization

    In Vitro

    (1978)
  • G. Carpenter et al.

    Antibodies to the epidermal growth factor receptor block the biological activities of sarcoma growth factor

  • L. Coussens et al.

    Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus

    Nature

    (1986)
  • B. Debuire et al.

    Sequencing the erbA gene of avian erythroblastosis virus reveals a new type of oncogene

    Science

    (1984)
  • R. Derynck et al.

    Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors

    Cancer Res.

    (1987)
  • P.P. Di Fiore et al.

    erbB-2 is a potent oncogene when overexpressed in NIH 3T3 cells

    Science

    (1987)
  • R.F. Doolittle et al.

    Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor

    Science

    (1983)
  • J. Downward et al.

    Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences

    Nature

    (1984)
  • R.N. Fabricant et al.

    Nerve growth factor receptors on human melanoma cells in culture

  • E. Finzi et al.

    The human transforming growth factor type alpha coding sequence is not a direct-acting oncogene when overexpressed in NIH 3T3 cells

  • Cited by (588)

    • The HER family as therapeutic targets in colorectal cancer

      2022, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      Different from the mutated HER2/neu gene in rodent tumors, the human HER2 gene is typically amplified in tumors, especially breast cancer in which 30% of tumors carry amplified HER2 gene (Kraus et al., 1987; Slamon et al., 1987). In addition, overexpression of wild-type HER2/neu gene in fibroblasts successfully transformed those cells (Di Fiore et al., 1987; Di Fiore et al., 1987; Hudziak et al., 1987), and HER2 overexpression was found to be an independent prognostic factor for patient survival in breast cancer (Slamon et al., 1987; van de Vijver et al., 1988). Those findings made HER2-positive breast cancer the most attractive target for the development of anti-HER2 therapies.

    • Targeting graphene quantum dots to epidermal growth factor receptor for delivery of cisplatin and cellular imaging

      2019, Materials Science and Engineering C
      Citation Excerpt :

      Herein, we present a non-cytotoxic, targeted, GQD-based nanocarrier with dual-functionality for delivery of CDDP and cellular imaging. The GQDs were targeted with a single chain variable fragment of antibody (scFvB10) to the EGFR, which is highly expressed in many cancerous cells than the normal ones [39–41]. The prepared nanocarriers leverage the unique properties of GQDs such as high drug loading capacity, fluorescence property and physiological stability.

    View all citing articles on Scopus
    View full text